GlassScriptPhysician profile
Russell L Brink
NPI 1780978171
$4,428.52
in general payments reported to CMS, 2019-2025
28 companies · $821 in 2025
The $821 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $414 · 2021: $539 · 2022: $578 · 2023: $827 · 2024: $818 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,366 · Education: $99.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,366.21 |
| Education | $99.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $661.37 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $466.99 | 2021-2025 | |
| Vifor Pharma, INC. | $462.24 | 2019-2025 | Veltassa |
| Amgen INC. | $261.03 | 2019-2025 | Krystexxa, Tavneos |
| Opko Pharmaceuticals, LLC | $259.94 | 2019-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $251.07 | 2021-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $248.97 | 2019-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $236.66 | 2023-2025 | |
| Travere Therapeutics, INC. | $190.71 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $190.52 | 2021-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $167.94 | 2023-2025 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $166.79 | 2019-2024 | Vafseo, Auryxia |
| Horizon Therapeutics Plc | $146.18 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $106.54 | 2023-2025 | Lupkynis |
| Ardelyx, INC. | $101.17 | 2024-2025 | Ibsrela |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $96.72 | 2019 | |
| Calliditas Therapeutics US INC. | $85.01 | 2022-2025 | Tarpeyo |
| Lilly USA, LLC | $59.19 | 2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $42.45 | 2022-2025 | Ultomiris |
| Genzyme Corporation | $42.03 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.48 | 2024 | Jardiance |
| Cormedix INC. | $31.73 | 2024 | Defencath |
| Medtronic, INC. | $26.86 | 2021 | |
| American Regent | $21.41 | 2023 | Injectafer |
| Scpharmaceuticals INC. | $20.11 | 2025 | |
| Apellis Pharmaceuticals, INC. | $19.31 | 2025 | Empaveli |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.66 | 2020 | |
| Abbott Laboratories | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Brink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.